JP7542935B2 - 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤 - Google Patents

溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤 Download PDF

Info

Publication number
JP7542935B2
JP7542935B2 JP2018556834A JP2018556834A JP7542935B2 JP 7542935 B2 JP7542935 B2 JP 7542935B2 JP 2018556834 A JP2018556834 A JP 2018556834A JP 2018556834 A JP2018556834 A JP 2018556834A JP 7542935 B2 JP7542935 B2 JP 7542935B2
Authority
JP
Japan
Prior art keywords
pla2
inhibitor
combination
envenomation
venom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018556834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514935A (ja
JP2019514935A5 (enExample
Inventor
マシュー・アール・ルウィン
Original Assignee
オフィレックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オフィレックス インコーポレイテッド filed Critical オフィレックス インコーポレイテッド
Publication of JP2019514935A publication Critical patent/JP2019514935A/ja
Publication of JP2019514935A5 publication Critical patent/JP2019514935A5/ja
Priority to JP2022135335A priority Critical patent/JP2022177020A/ja
Application granted granted Critical
Publication of JP7542935B2 publication Critical patent/JP7542935B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2018556834A 2016-04-29 2017-05-01 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤 Active JP7542935B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022135335A JP2022177020A (ja) 2016-04-29 2022-08-26 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329611P 2016-04-29 2016-04-29
US62/329,611 2016-04-29
US201662340075P 2016-05-23 2016-05-23
US62/340,075 2016-05-23
US201662423693P 2016-11-17 2016-11-17
US62/423,693 2016-11-17
PCT/US2017/030436 WO2017190141A1 (en) 2016-04-29 2017-05-01 Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022135335A Division JP2022177020A (ja) 2016-04-29 2022-08-26 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤

Publications (3)

Publication Number Publication Date
JP2019514935A JP2019514935A (ja) 2019-06-06
JP2019514935A5 JP2019514935A5 (enExample) 2020-06-18
JP7542935B2 true JP7542935B2 (ja) 2024-09-02

Family

ID=60161200

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018556834A Active JP7542935B2 (ja) 2016-04-29 2017-05-01 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤
JP2022135335A Pending JP2022177020A (ja) 2016-04-29 2022-08-26 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022135335A Pending JP2022177020A (ja) 2016-04-29 2022-08-26 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤

Country Status (9)

Country Link
US (2) US12383531B2 (enExample)
EP (1) EP3448378B1 (enExample)
JP (2) JP7542935B2 (enExample)
KR (2) KR102723249B1 (enExample)
CN (2) CN109562098B (enExample)
AU (2) AU2017257185B8 (enExample)
IL (2) IL262620B2 (enExample)
MX (2) MX391165B (enExample)
WO (1) WO2017190141A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7542935B2 (ja) 2016-04-29 2024-09-02 オフィレックス インコーポレイテッド 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤
WO2023086343A1 (en) * 2021-11-09 2023-05-19 Ophirex, Inc. Compositions and dosage forms for topical and transdermal delivery of actives and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029726A1 (en) 1997-12-05 1999-06-17 Hsc (Pla) Pty. Ltd. Phospholipase inhibitor
US20080096963A1 (en) 2004-07-21 2008-04-24 Cerep Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
SI0675110T1 (en) * 1994-04-01 2002-12-31 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibitors
DE69716619T2 (de) * 1996-08-28 2003-06-26 The Procter & Gamble Company, Cincinnati Phosphinsäureamide als matrix metalloprotease inhibitoren
GB2365769A (en) * 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
US8106019B2 (en) * 2002-11-15 2012-01-31 Philadelphia Health & Education Corporation CHEC-7 a novel sPLA2 inhibitor
AU2004270261B2 (en) * 2003-09-09 2008-12-04 University Of Florida Research Foundation, Inc. Polyamine-metal chelator conjugates
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
US20100204249A1 (en) * 2009-01-08 2010-08-12 Colin Hislop Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
US20110269786A1 (en) * 2010-04-30 2011-11-03 Colin Hislop Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US20140087003A1 (en) * 2012-09-21 2014-03-27 Ignacio Cisneros Method for treating venomous bites and stings
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10786483B2 (en) * 2016-03-04 2020-09-29 Hk Pharma Tumescent contravenom drug delivery
JP7542935B2 (ja) 2016-04-29 2024-09-02 オフィレックス インコーポレイテッド 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのｐｌａ２およびｈｍｇ－ｃｏａ阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029726A1 (en) 1997-12-05 1999-06-17 Hsc (Pla) Pty. Ltd. Phospholipase inhibitor
US20080096963A1 (en) 2004-07-21 2008-04-24 Cerep Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｅｘｐｅｒｔ Ｏｐｉｎ．Ｔｈｅｒ．Ｐａｔｅｎｔｓ（２０１３），２３（３），ｐ．３３３－３４４
Ｐｌａｎｔａ Ｍｅｄｉｃａ，１９９２，５８，ｐ．５４９－５５１

Also Published As

Publication number Publication date
MX2018013084A (es) 2019-03-06
CN109562098A (zh) 2019-04-02
US20250120949A1 (en) 2025-04-17
JP2022177020A (ja) 2022-11-30
MX2022003739A (es) 2022-05-02
AU2017257185B9 (en) 2023-07-06
AU2023233187A1 (en) 2023-10-12
KR20230049762A (ko) 2023-04-13
CN116585306A (zh) 2023-08-15
US12383531B2 (en) 2025-08-12
WO2017190141A1 (en) 2017-11-02
AU2017257185A1 (en) 2018-11-22
KR102723249B1 (ko) 2024-10-28
JP2019514935A (ja) 2019-06-06
EP3448378C0 (en) 2024-04-17
EP3448378A1 (en) 2019-03-06
IL262620A (en) 2018-12-31
EP3448378B1 (en) 2024-04-17
CN109562098B (zh) 2023-04-21
MX391165B (es) 2025-03-21
AU2017257185B8 (en) 2023-07-06
IL262620B1 (en) 2023-10-01
IL307232B1 (en) 2025-12-01
BR112018072162A2 (pt) 2019-02-12
IL262620B2 (en) 2024-02-01
CA3022013A1 (en) 2017-11-02
CN116585306B (zh) 2025-06-20
US20210220332A1 (en) 2021-07-22
IL307232A (en) 2023-11-01
EP3448378A4 (en) 2020-04-08
AU2017257185B2 (en) 2023-06-22
KR20190005898A (ko) 2019-01-16

Similar Documents

Publication Publication Date Title
US12274691B2 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
US20250120949A1 (en) Use of spla2 inhibitors to treat envenomation by snakes and wasps
CZ20013149A3 (cs) Léčivo proti chronické obstrukční pulmonární chorobě a způsob jeho výroby
US20250120950A1 (en) Use of spla2 inhibitors to treat hymenoptera envenomation, hemolysis, and kidney disease, and to protect blood from osmotic fragility
CA3022013C (en) Secreted pla2 inhibitors for immediate treatment of hymenoptera envenomation
HK40006646B (en) Pla2 inhibitors for immediate treatment of hymenoptera envenomation and other conditions caused by histamine release
HK40006646A (en) Pla2 inhibitors for immediate treatment of hymenoptera envenomation and other conditions caused by histamine release
BR112018072162B1 (pt) Uso de um inibidor de molécula pequena da fosfolipase a2 (pla2)
HK1239573B (zh) 毒液蛰入治疗方法及相关药物组合物、系统和试剂盒
HK1239573A1 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220826

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220906

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221013

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221028

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240821

R150 Certificate of patent or registration of utility model

Ref document number: 7542935

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150